Siena Biotech SpA, of Siena, Italy, received an undisclosed milestone payment from Roche AG, of Basel, Switzerland, stemming from the firms' 2007 neurodegenerative disease collaboration. Roche exercised its option last year to take the lead on developing and commercializing selected molecules for treating Alzheimer's disease.